CXCR4‐CMVs loaded with curcumin could maintain drug stability and activity, suppress the inflammatory reaction in vitro and demonstrate selective targeting and anti‐inflammatory effects on IBD and AP animal models. This evidence concerns the gene CXCR4 and inflammatory bowel disease.